Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
At a glance
- $BHVN today−4.35%last $13.20
- Vs industry peers−3.23 pts6-peer median −1.11% · far behind
- Since Sep 10+3.86%from the first trade after the story
- 52-week range27.6% below high$8.03 – $18.24
- Cash runway~3 mo$95.8M cash ÷ $38.1M/mo burn · 10-Q
- Sector scannerCalmHealth Care
Nothing reported about biohaven across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $BHVN -4.35% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Biohaven ($BHVN) dropped 4.35% to $13.20 in the latest session. Over the past month it is up 16.7%. That leaves it 28% below its 52-week high of $18.24 and 64% above its low of $8.03. The year's high was 2.3 times its low, which makes double-digit swings fairly routine here.
What the filings say
In its latest report (10-Q, filed Oct 29, 2026), $BHVN lost $129.3M over the quarter to Sep 30, 2026. Operations used $341.9M of cash over the nine months to Sep 30, 2026 — about $38.1M a month — against $95.8M in cash on Sep 30, 2026. At that pace the cash covers about 3 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $361.9M against $95.8M of cash on Sep 30, 2026. Liabilities of $361.9M exceeded assets of $263.7M on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Sep 10, the same day as this story; it is $BHVN's own account and the first thing to read. Figures are as filed with the SEC; the $BHVN page has the full statements.
How much coverage it is getting
Nothing new on Biohaven has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $BHVN page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $BHVN: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on September 10, 2026. $BHVN has moved +3.86% ($12.71 to $13.20). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
